Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per ...

two purchases of Moderna's stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel's company, called ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.

Is MRNA stock a sell? Investing.com -- Citi has ... Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per share.

The questions on investors' minds right now are the effectiveness of MRNA's business, the public's view of the company, and whether the stock will fall below its IPO price. I will try to answer ...

If an investor was to purchase shares of MRNA stock at the current price level of $30.70/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases by the CEO and director. This comes as a significant ...